Search

Your search keyword '"Maurer, Mathew S"' showing total 2,081 results
Start Over Author "Maurer, Mathew S"
2,081 results on '"Maurer, Mathew S"'

4. Review and Analysis of Existing Mobile Phone Apps to Support Heart Failure Symptom Monitoring and Self-Care Management Using the Mobile Application Rating Scale (MARS)

Author

Masterson Creber, Ruth M, Maurer, Mathew S, Reading, Meghan, Hiraldo, Grenny, Hickey, Kathleen T, and Iribarren, Sarah

Subjects
Information technology, T58.5-58.64, Public aspects of medicine, RA1-1270
Abstract

BackgroundHeart failure is the most common cause of hospital readmissions among Medicare beneficiaries and these hospitalizations are often driven by exacerbations in common heart failure symptoms. Patient collaboration with health care providers and decision making is a core component of increasing symptom monitoring and decreasing hospital use. Mobile phone apps offer a potentially cost-effective solution for symptom monitoring and self-care management at the point of need. ObjectiveThe purpose of this review of commercially available apps was to identify and assess the functionalities of patient-facing mobile health apps targeted toward supporting heart failure symptom monitoring and self-care management. MethodsWe searched 3 Web-based mobile app stores using multiple terms and combinations (eg, “heart failure,” “cardiology,” “heart failure and self-management”). Apps meeting inclusion criteria were evaluated using the Mobile Application Rating Scale (MARS), IMS Institute for Healthcare Informatics functionality scores, and Heart Failure Society of America (HFSA) guidelines for nonpharmacologic management. Apps were downloaded and assessed independently by 2-4 reviewers, interclass correlations between reviewers were calculated, and consensus was met by discussion. ResultsOf 3636 potentially relevant apps searched, 34 met inclusion criteria. Most apps were excluded because they were unrelated to heart failure, not in English or Spanish, or were games. Interrater reliability between reviewers was high. AskMD app had the highest average MARS total (4.9/5). More than half of the apps (23/34, 68%) had acceptable MARS scores (>3.0). Heart Failure Health Storylines (4.6) and AskMD (4.5) had the highest scores for behavior change. Factoring MARS, functionality, and HFSA guideline scores, the highest performing apps included Heart Failure Health Storylines, Symple, ContinuousCare Health App, WebMD, and AskMD. Peer-reviewed publications were identified for only 3 of the 34 apps. ConclusionsThis review suggests that few apps meet prespecified criteria for quality, content, or functionality, highlighting the need for further refinement and mapping to evidence-based guidelines and room for overall quality improvement in heart failure symptom monitoring and self-care related apps.

Published
2016
Full Text
View/download PDF

6. Wild-Type ATTR Amyloidosis

Author

Perfetto, Federico, Cappelli, Francesco, Panichella, Giorgia, Argirò, Alessia, Maurer, Mathew S., Emdin, Michele, editor, Vergaro, Giuseppe, editor, Aimo, Alberto, editor, and Fontana, Marianna, editor

Published
2024
Full Text
View/download PDF

7. Limited English Proficiency in Older Adults Referred to the Cardiovascular Team.

Author

Medrano, Francisco J, Fernandez, Alicia J, Sudore, Rebecca L, Kirkpatrick, James N, Benda, Natalie C, Creber, Ruth Masterson, Goyal, Parag, Beavers, Craig, Maurer, Mathew S, Rich, Michael W, Alexander, Karen P, Krishnaswami, Ashok, and Geriatric Cardiology and Cardiovascular Team Councils of the American College of Cardiology

Subjects
Geriatric Cardiology and Cardiovascular Team Councils of the American College of Cardiology, Humans, Communication Barriers, Language, Aged, Limited English Proficiency, Cardiovascular disease, Geriatrics, Language barriers, Language interpreter services, Limited English proficiency, Older adults, Technology, Clinical Research, Patient Safety, Aging, Health Services, Cardiovascular, 8.1 Organisation and delivery of services, Health and social care services research, 7.3 Management and decision making, Management of diseases and conditions, Good Health and Well Being, Medical and Health Sciences, General & Internal Medicine
Abstract

Limited English proficiency (LEP) is defined as individuals in whom English is not the primary language and who have limited ability to read, speak, write, or understand the English language. Cardiovascular (CV) team members routinely encounter language barriers in their practice. These barriers have a significant impact on the quality of CV care that patients with LEP receive. Despite evidence demonstrating the negative association between language barriers and health disparities, the impact on CV care is insufficiently known. In addition, older adults with CV disease and LEP are facing increasing risk of adverse events when complex medical information is not optimally delivered. Overcoming language barriers in CV care will need a thoughtful approach. Although well recognized, the initial step will be to continue to highlight the importance of language needs identification and appropriate use of professional interpreter services. In parallel, a health system-level approach is essential that describes initiatives and key policies to ensure a high-level quality of care for a growing LEP population. This review aims to present the topic of LEP during the CV care of older adults, for continued awareness along with practical considerations for clinical use and directions for future research.

Published
2023

8. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases

Author

Chan, Nicholas, Einstein, Andrew J., Griffin, Jan M., Rosenblum, Hannah, Teruya, Sergio, Cuomo, Margaret, De Los Santos, Jeffeny, DeLuca, Albert, Johnson, Lynne L., Kinkhabwala, Mona P., Leb, Jay S., Mintz, Akiva, Fine, Denise, Helmke, Stephen, Muralidhar, Varsha, Pandey, Shivda, Sabogal, Natalia, Saith, Sunil E., Winburn, Morgan, Smiley, Dia, Miller, Edward J., Ruberg, Frederick L., and Maurer, Mathew S.

Published
2023
Full Text
View/download PDF

9. Mosaic Loss of the Y Chromosome Is Enriched in Patients With Wild-Type Transthyretin Cardiac Amyloidosis and Associated With Increased Mortality

Author

Thel, Mark C., Cochran, Jesse D., Teruya, Sergio, Hayashi, Ou, Xie, Christopher R., Srinivasan, Ajay R., Chavkin, Nicholas W., Arai, Yohei, Sano, Soichi, Mirabal Santos, Alfonsina, De Los Santos, Jeffeny, Fine, Denise, Sabogal, Natalia, Ullah, Ikram, Helmke, Stephen, Rodriguez, Carlos, Prokaeva, Tatiana, Foster, Rachel H., Spencer, Brian H., Izumiya, Yasuhiro, Maurer, Mathew S., Walsh, Kenneth, and Ruberg, Frederick L.

Published
2024
Full Text
View/download PDF

14. Comprehensive Geriatric Assessment to Optimize the Management of Older Patients With Transthyretin Cardiac Amyloidosis

Author

Fumagalli, Carlo, Maurer, Mathew S., Fontana, Marianna, Fine, Nowell, Gillmore, Julian, Goyal, Parag, Nakagawa, Shunichi, Musumeci, Beatrice, Grogan, Martha, Marfella, Raffaele, Limongelli, Giuseppe, Bo, Mario, Longhi, Simone, Cuddy, Sarah, Masri, Ahmad, Olivotto, Iacopo, Perfetto, Federico, Ungar, Andrea, Marchionni, Niccolò, and Cappelli, Francesco

Published
2024
Full Text
View/download PDF

18. Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS

Author

Emdin, Michele, Hanna, Mazen, Azevedo, Olga, Lino Cirami, Calogero, Gonzalez Costello, Jose, Slosky, David, Moelgaard, Henning, Nativi Nicolau, Jose, Hummel, Scott, Jeon, Eun-Seok, Fine, Nowell, Murali, Srinivas, Miller, Edward, Shah, Sanjiv, Witteles, Ronald, Waddington-Cruz, Marcia, Lenihan, Daniel, Sekijima, Yoshiki, Van Cleemput, Johan, Correia, Edileide de Barros, Cariou, Eve, Quan, Dianna, Freimer, Miriam, Steidley, David, Hüsing-Kabar, Anna, Plante-Bordeneuve, Violaine, Nienhuis, Hans, Wixner, Jonas, Ralph, Jeffrey, Ventura, Hector, Zivkovic, Sasa, Delgado, Diego, Fernandéz Torrón, Roberto, Gottlieb, Stephen, Cotts, William, Tallaj, Jose, Brunkhorst, Robert, Polydefkis, Michael, Mueller, Christopher, Tschoepe, Carsten, Gonzalez Moreno, Juan, Sarswat, Nitasha, Luo, Jin, Tauras, James, Warner, Alberta, Mora-Ayestaran, Nerea, Dispenzieri, Angela, Kristen, Arnt V., Maurer, Mathew S., Diemberger, Igor, Drachman, Brian M., Grogan, Martha, Gupta, Pritam, Glass, Oliver, Amass, Leslie, and Garcia-Pavia, Pablo

Published
2024
Full Text
View/download PDF

24. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Author

Gentile, Luca, Coelho, Teresa, Dispenzieri, Angela, Conceição, Isabel, Waddington-Cruz, Márcia, Kristen, Arnt, Wixner, Jonas, Diemberger, Igor, Gonzalez-Moreno, Juan, Cariou, Eve, Maurer, Mathew S., Planté-Bordeneuve, Violaine, Garcia-Pavia, Pablo, Tournev, Ivailo, Gonzalez-Costello, Jose, Duarte, Alejandra Gonzalez, Grogan, Martha, Mazzeo, Anna, Chapman, Doug, Gupta, Pritam, Glass, Oliver, and Amass, Leslie

Published
2023
Full Text
View/download PDF

25. Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study

Author

Pandey, Shivda, Teruya, Sergio, Rodriguez, Carlos, Deluca, Albert, Kinkhabwala, Mona, Johnson, Lynne L., Fine, Denise, Sabogal, Natalia, Winburn, Morgan, Castillo, Michelle, Bhatia, Ketan, Malkovskaya, Rita, Raiszadeh, Farbod, Kurian, Damian, Miller, Edward J., Einstein, Andrew J., Maurer, Mathew S., and Ruberg, Frederick L.

Published
2023
Full Text
View/download PDF

28. The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology

Author

STERN, LILY K., GRODIN, JUSTIN L., MAURER, MATHEW S., RUBERG, FREDERICK L., PATEL, AYAN R., KHOURI, MICHEL G., ROTH, LORI R., ARAS, MANDAR A., BHARDWAJ, ANJU, BHATTACHARYA, PRIYANKA, BRAILOVSKY, YEVGENIY, DRACHMAN, BRIAN M., EBONG, IMO A., FINE, NOWELL M., GAGGIN, HANNA, GOPAL, DEEPA, GRIFFIN, JAN, JUDGE, DANIEL, KIM, PAUL, MITCHELL, JOSHUA, MITTER, SUMEET S., MOHAN, RAJEEV C., RAMOS, HANNIA, REYENTOVICH, ALEX, SHEIKH, FAROOQ H., SPERRY, BRETT, CARTER, SPENCER, UREY, MARCUS, VAISHNAV, JOBAN, VEST, AMANDA R., KITTLESON, MICHELLE M., and PATEL, JIGNESH K.

Published
2024
Full Text
View/download PDF

32. Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life

Author

Cohen, Laura P, Vittinghoff, Eric, Pletcher, Mark J, Allen, Norrina B, Shah, Sanjiv J, Wilkins, John T, Chang, Patricia P, Ndumele, Chiadi E, Newman, Anne B, Ives, Diane, Maurer, Mathew S, Oelsner, Elizabeth C, Moran, Andrew E, and Zhang, Yiyi

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Hypertension, Atherosclerosis, Aging, Prevention, Clinical Research, Cardiovascular, Heart Disease, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Adult, Cardiovascular Diseases, Female, Heart Disease Risk Factors, Heart Failure, Humans, Male, Prognosis, Risk Factors, Stroke Volume, Heart failure subtype, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, risk factors, midlife, Cardiorespiratory Medicine and Haematology, Nursing, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences
Abstract

BackgroundIndependent associations between cardiovascular risk factor exposures during midlife and later life development of heart failure (HF) with preserved ejection fraction (HFpEF) versus reduced EF (HFrEF) have not been previously studied.MethodsWe pooled data from 4 US cohort studies (Atherosclerosis Risk in Communities, Cardiovascular Health, Health , Aging and Body Composition, and Multi-Ethnic Study of Atherosclerosis) and imputed annual risk factor trajectories for body mass index, systolic and diastolic blood pressure, low-density lipoprotein and high-density lipoprotein cholesterol, and glucose starting from age 40 years. Time-weighted average exposures to each risk factor during midlife and later life were calculated and analyzed for associations with the development of HFpEF or HFrEF.ResultsA total of 23,861 participants were included (mean age at first in-person visit, 61.8 ±1 0.2 years; 56.6% female). During a median follow-up of 12 years, there were 3666 incident HF events, of which 51% had EF measured, including 934 with HFpEF and 739 with HFrEF. A high midlife systolic blood pressure and low midlife high-density lipoprotein cholesterol were associated with HFrEF, and a high midlife body mass index, systolic blood pressure, pulse pressure, and glucose were associated with HFpEF. After adjusting for later life exposures, only midlife pulse pressure remained independently associated with HFpEF.ConclusionsMidlife exposure to cardiovascular risk factors are differentially associated with HFrEF and HFpEF later in life. Having a higher pulse pressure during midlife is associated with a greater risk for HFpEF but not HFrEF, independent of later life exposures.

Published
2021

35. Inclusion of Performance Parameters and Patient Context in the Clinical Practice Guidelines for Heart Failure

Author

Goyal, Parag, Unlu, Ozan, Kennel, Peter J, Schumacher, Ross C, Gilstrap, Lauren G, Krishnaswami, Ashok, Allen, Larry A, Maurer, Mathew S, Rich, Michael W, and Makam, Anil

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Cardiovascular, Heart Disease, Good Health and Well Being, American Heart Association, Cardiology, Heart Failure, Humans, United States, Heart failure, evidence-based medicine, decision-making, practice guidelines, Cardiorespiratory Medicine and Haematology, Nursing, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences
Abstract

BackgroundTo facilitate evidence-based medicine (EBM) on an individual level, it may be important for clinical practice guidelines (CPGs) to incorporate the performance parameters of diagnostic studies and therapeutic interventions (such as likelihood ratio and absolute benefit or harm), and to incorporate relevant patient contexts that may influence decision-making. We sought to determine the extent to which heart failure CPGs currently incorporate this information.MethodsWe reviewed the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) 2013 Heart Failure CPG, the 2017 ACCF/AHA/HFSA update, and European Society of Cardiology (ESC) 2016 Heart Failure CPG. We abstracted variables for each CPG recommendation from the following domains: quality of evidence, strength of recommendation, diagnostic and therapeutic performance parameters, and patient context.ResultsWe examined 169 recommendations from the ACCF/AHA 2013 CPGs and 2017 update and 187 recommendations from the 2016 ESC CPGs. Performance parameters for diagnostic studies (2013 ACCF/AHA: 13%; 2017 ACCF/AHA/HFSA update: 0%; 2016 ESC: 0%) and therapeutic interventions (2013 ACCF/AHA: 65%; 2017 ACCF/AHA/HFSA update: 64%; 2016 ESC: 16%) were not commonly included in CPGs. Patient context was included in about half of ACCF/AHA recommendations and a quarter of ESC recommendations.ConclusionsThe majority of recommendations from heart failure CPGs lack information on diagnostic and therapeutic performance parameters and patient context. Given the importance of these components to effectively implement EBM, particularly for a heterogeneous heart failure population, innovative strategies are needed to optimize CPGs so they provide comprehensive yet succinct recommendations that can improve population-level outcomes and ensure optimal patient-centered care.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results